(firstQuint)Evaluation of the Efficacy of Cesamet for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy.

 To determine the safety and efficacy of Cesamet cent in the symptomatic treatment of chemotherapy-induced neuropathic pain.

 This is a phase IV, multicenter, open label of Cesamet cent at 1 mg daily progressing to 2mg BID in subjects with chemotherapy-induced neuropathic pain.

 This study has two phases: A pretreatment phase and a treatment phase.

.

 Evaluation of the Efficacy of Cesamet for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy@highlight

This study was designed to evaluate the safety and efficacy of Cesamet cent in controlling pain in subjects experiencing pain due to chemotherapy-induced neuropathic pain in patients with cancer.

